A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Inclusion Criteria

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• Histological diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer according to World of Health Organization (WHO) 2020 classification
• Recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer, as described in the protocol
• Serum cancer antigen (CA) 125 ≥ 2 × upper limit of normal (ULN) as assessed at the local lab by a 510(k) cleared test at screening
• Participants must have at least 1 measurable tumor lesion as defined by the response evaluation criteria in solid tumors (RECIST) 1.1.
• Expected survival ≥ 3 months Key

Exclusion Criteria

• Inadequate cardiovascular, renal and hepatic function, as described in the protocol
• Absolute lymphocyte count (ALC) < 100 cells/μL at time of leukapheresis
• History of Grade ≥ 2 hemorrhage within 30 days, or inadequate coagulation parameters, as described in the protocol
• Known history or presence of clinically relevant central nervous system (CNS) pathology, as described in the protocol
• Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune related adverse events (AEs)
• Treatment with any cellular or gene therapy Note: Other protocol-defined Inclusion/Exclusion criteria apply